ALBUMIN FUSION TECHNOLOGY: ADVANCING THE TREATMENT OF HEMOPHILIA B

IDELVION uses albumin fusion technology to extend half-life with minimal risk of an immune response

Recombinant albumin

Recombinant albumin, known for its long half-life and low risk for immunogenic reaction, is fused with recombinant Factor IX (rFIX) to form IDELVION

Cleavable peptide linker

Upon initiation of the coagulation cascade, recombinant albumin is cleaved, releasing only activated FIX when needed for coagulation

rFIX

IDELVION remains intact in the bloodstream until Factor IX (FIX) is activated, resulting in maximum factor activity

Albumin fusion technology diagram for IDELVION Learn about recombinant albumin Learn about recombinant FIX Learn about cleavable peptide linker

Zero median annualized spontaneous bleeding rate (AsBR) when dosed at 7 and 14 days in clinical trials

VIEW EFFICACY DATA
You are now leaving the current website.

Do you want to continue?

No Yes